Zura Bio posts $25.8 million net loss in third quarter of 2026
Key Facts
Zura Bio reported results for the third quarter ended September 30, 2026, posting a net loss of $25.8 million, compared with $20.0 million in the same period of 2025, according to the company statement published via Business Wire. The loss was $0.20 per share, versus $0.21 per share a year earlier. This means the net loss widened year over year, while the loss per share narrowed marginally. The announcement did not establish whether the per-share loss was in line with analyst estimates. The results come as the company continues to fund its clinical programs, with its announced upcoming milestones focused on results from two studies and the start of a new study.
Research spending was the largest of the rising expense items, reaching $19.5 million in the third quarter of 2026, up from $11.9 million in the corresponding period of 2025, according to the company statement. Zura Bio attributed the increase to the continuation of its Phase 2 tibulizumab program and activities to initiate the NEXUS-PMR study. The spending reflects progress in the company's clinical programs during the period and links part of the expense increase to preparations for a new study. The statement did not provide a separate cost figure for either program. This comparison alone also does not show how much each activity contributed to the year-over-year increase.
General and administrative expenses rose to $9.3 million in the third quarter, from $7.6 million a year earlier, the company said. Zura Bio attributed the increase mainly to higher professional fees. Alongside research and development, this item contributed to the higher net loss compared with the same period of 2025. The comparison shows that the increase in expenses was not limited to funding research programs, although research spending was the larger of the two items cited in the statement. The company provided no further breakdown of the professional fees in its disclosure.
Cash and cash equivalents totaled $187.7 million on September 30, 2026, and the company said it expects its current liquidity to support planned operations through at least the end of 2028. This estimate sets a timeframe for funding the activities Zura Bio has announced, including continuing the clinical trials on its schedule. The company thereby links its cash balance at the end of September with its operating plans for the coming period. The estimate remains the company's forecast, and the statement did not mention any revision after the third-quarter results were announced. Near-term milestones include topline data expected from TibuSHIELD, followed by results from the TibuSURE study in 2027.
Enrollment in the Phase 2 TibuSHIELD study was completed in June 2026, with 247 participants, and topline results remain expected in the fourth quarter of 2026, according to Zura Bio's statement. Completion of enrollment puts the study at the results follow-up stage, after the participants underpinning the anticipated initial announcement have joined. Enrollment in the Phase 2 TibuSURE study was completed in July 2026, with 91 participants. The company said topline results remain expected in the first half of 2027. The announced timeline sets out two milestones at different times for the programs: the first in the fourth quarter of 2026, followed by the other in the first half of the next year.
Zura Bio plans to start a Phase 2 study of tibulizumab for polymyalgia rheumatica, NEXUS-PMR, by the end of 2026. The company said the U.S. Food and Drug Administration had allowed the study to proceed under an investigational new drug application, and that its start remains on track for year-end. The company also linked activities to initiate the study to higher research and development expenses during the quarter. The announced milestones thus combine topline results from two trials that have completed enrollment with a new trial scheduled to begin before the end of 2026. ZURA shares closed at $3.56 on October 26, 2026, according to EL7 data.